MONTREAL, CANADA--(Marketwired - Apr 9, 2013) - Mr. Paul Pommier, Chair of the Board of Directors of Theratechnologies Inc. (Theratechnologies) (TH.TO), today announced the appointment of Mrs. Dawn Graham as a member of its Board.
Until recently, Dawn Graham was president of the Europe/Canada region for Merck & Co., a multinational pharmaceutical corporation. This position represented the culmination of a 23 year career with this corporation. She had previously served as president of Merck Canada. At that time, she was returning from a two year stay abroad where she held the positions of Vice President, Asia Pacific, and, prior to this, Vice President, Global Marketing for the Arthritis, Analgesics and Osteoporosis franchise. She had previously particularly distinguished herself at Merck Canada as Vice President, Sales, and Vice President, Corporate Affairs.
Board members and its current Chair, Paul Pommier, intend, if they are re-elected during the next annual meeting of shareholders to be held on May 24, to appoint Mrs. Graham as Chair of the Board of Directors at the meeting of the Board that will be held immediately after the annual meeting.
"Dawn has a strong and vast experience of the Canadian and international pharmaceutical sectors. Her knowledge represents an important asset for Theratechnologies' Board which will undoubtedly benefit from her strategic vision as we pursue our goal to create greater value for tesamorelin," said Paul Pommier, Chair of Theratechnologies' Board of Directors.
"I am proud to be joining the ranks of Theratechnologies. As I am very familiar with the issues that biopharmaceutical companies are facing, I intend to support the Board by building on the experience I have acquired in the industry over the last thirty years and thus promote Theratechnologies' development," added Dawn Graham, member of Theratechnologies' Board of Directors.
Over and above the positions she held at Merck, Mrs. Graham also served as Chair of the Board of Directors of Rx&D, the national association representing research-based pharmaceutical companies in Canada, as well as Chair of the Board of the Merck/Schering-Plough joint venture. She has also been an active member on many boards of directors.
A Montreal-native, Mrs. Graham is bilingual.
Theratechnologies (TH.TO) is a biopharmaceutical company that specializes in innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on the Securities and Exchange Commission's website at www.sec.gov.